Quoin Pharmaceuticals Ltd. (QNRX)
6.93
-0.04
(-0.57%)
USD |
NASDAQ |
Sep 10, 16:00
6.93
0.00 (0.00%)
After-Hours: 16:25
Quoin Pharmaceuticals Enterprise Value : 3.198M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 3.198M |
| September 08, 2026 | 3.560M |
| September 04, 2026 | 3.781M |
| September 03, 2026 | 5.006M |
| September 02, 2026 | 2.737M |
| September 01, 2026 | 2.275M |
| August 31, 2026 | 1.692M |
| August 28, 2026 | 1.491M |
| August 27, 2026 | -0.4467M |
| August 26, 2026 | -0.3965M |
| August 25, 2026 | -0.6174M |
| August 24, 2026 | 0.0855M |
| August 21, 2026 | 0.3868M |
| August 20, 2026 | -0.7781M |
| August 19, 2026 | -1.320M |
| August 18, 2026 | -0.8183M |
| August 17, 2026 | -0.3764M |
| August 14, 2026 | -0.5772M |
| August 13, 2026 | 1.351M |
| August 12, 2026 | 1.030M |
| August 11, 2026 | -0.0551M |
| August 10, 2026 | -0.035M |
| August 07, 2026 | -1.180M |
| August 06, 2026 | -1.622M |
| August 05, 2026 | -2.023M |
| Date | Value |
|---|---|
| August 04, 2026 | -2.064M |
| August 03, 2026 | -1.863M |
| July 31, 2026 | -1.863M |
| July 30, 2026 | -1.963M |
| July 29, 2026 | -2.214M |
| July 28, 2026 | -2.365M |
| July 27, 2026 | -2.184M |
| July 24, 2026 | -2.204M |
| July 23, 2026 | -2.023M |
| July 22, 2026 | -2.013M |
| July 21, 2026 | -2.244M |
| July 20, 2026 | -2.345M |
| July 17, 2026 | -2.284M |
| July 16, 2026 | -2.445M |
| July 15, 2026 | -2.345M |
| July 14, 2026 | -2.064M |
| July 13, 2026 | -2.304M |
| July 10, 2026 | -1.863M |
| July 09, 2026 | -1.421M |
| July 08, 2026 | -1.320M |
| July 07, 2026 | -1.160M |
| July 06, 2026 | -1.561M |
| July 02, 2026 | -1.602M |
| July 01, 2026 | -1.340M |
| June 30, 2026 | -1.079M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.882B |
| Alnylam Pharmaceuticals, Inc. | 34.18B |
| Anika Therapeutics, Inc. | 266.28M |
| Savara, Inc. | 969.61M |
| Vericel Corp. | 1.927B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.463M |
| Total Expenses (Quarterly) | 5.463M |
| EPS Diluted (Quarterly) | -2.720 |
| Earnings Yield | -215.4% |
| Normalized Earnings Yield | -215.49 |